Skip to main content

PharmaCyte Biotech, Inc.

PMCB
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001157075

No open-market purchases or sales by PharmaCyte Biotech, Inc. insiders were filed in the last 90 days; 32 institutions reported holding it in 13F filings for Q2 2026, worth $586.2K in total; no superinvestor holds it.

Q2 2026 vs. Q1 2026

How the institutions holding PharmaCyte Biotech, Inc. changed between Q1 2026 and Q2 2026.

All holders in Q2 2026All holders in Q1 2026

13F holders of PMCB: Q1 2026 compared with Q2 2026
MeasureQ1 2026Of which not filed for Q2 2026Q2 2026Change
Holders36132−3
Shares967.6K1762.8K−204.8K (−21.2%)
Value$643.2K$1$586.2K−$56.9K (−8.9%)

1 institution that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so the changes leave them out.

New holders (3)

Institutions that held PharmaCyte Biotech, Inc. at the end of Q2 2026 but not at the end of Q1 2026.

Institutions new to PMCB in Q2 2026
InstitutionSharesValue% of portfolio
Susquehanna International Group, LLP44,853$34.5K0.00%
Barclays PLC192$1480.00%
CoreCap Advisors, LLC4$30.00%

Sold out (6)

Institutions that held PharmaCyte Biotech, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.

Institutions that sold out of PMCB in Q2 2026
InstitutionShares, Q1 2026Value, Q1 2026
Virtu Financial LLC37,532$25.0K
Simplex Trading, LLC19,940$13.3K
Two Sigma Securities, LLC16,360$10.9K
Ground Swell Capital, LLC11,527$7.67K
Abound Wealth Management1$1
Fortitude Family Office, LLC1$1

Not filed for Q2 2026 yet (1)

Institutions that held PharmaCyte Biotech, Inc. at the end of Q1 2026 and haven't filed a 13F for Q2 2026. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding PMCB in Q1 2026 that haven't filed for Q2 2026
InstitutionShares, Q1 2026Value, Q1 2026
CWM, LLC1$1